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Abstract
Extensive genetic, biochemical, and histological evidence has implicated the amyloid-β peptide (Aβ)
in Alzheimer's disease pathogenesis, and several mechanisms have been suggested, such as metal
binding, reactive oxygen species production, and membrane pore formation. However, recent
evidence argues for an additional role for signaling mediated by the amyloid precursor protein, APP,
in part via the caspase cleavage of APP at aspartate 664. Here we review the effects and implications
of this cleavage event, and propose a model of Alzheimer's disease that focuses on the critical
nature of this cleavage and its downstream effects.
Review: programmed cell death, cell death 
signaling, and neurodegenerative disease
Many of the diseases that affect the nervous system feature
an abnormality of cell death of one sort or another: for
example, developmental and neoplastic disorders of the
nervous system feature dysregulation of the intrinsic cellu-
lar programs that mediate cell death. Such dysregulation
may also occur in neurodegenerative, infectious, trau-
matic, ischemic, metabolic, and demyelinating disorders.
Therefore, targeting the central biochemical controls of
cell survival and death may potentially represent a pro-
ductive therapeutic approach. Furthermore, recent results
from stem cell studies suggest that the fate of neural stem
cells may also play an important role in disease outcomes,
and therefore cell death apparently plays a central role in
many neurological diseases, and potentially in their pre-
vention and treatment.
Early studies of neuronal survival focused on the status of
external factors such as pH, glucose availability, and the
partial pressure of oxygen. While these are clearly critical
determinants, research over the past few decades has
revealed a more active, and more plastic, role for the cell
in its own life/death decision than was previously appre-
ciated. Complementing this concept, studies of the inter-
nal suicide programs of neural cells have offered new
potential targets for therapeutic development.
In neurodegenerative diseases such as Alzheimer's disease,
neurons in various nuclei are lost in disease-specific distri-
butions. However, the neuronal loss is a relatively late
event, typically following synaptic dysfunction, synaptic
loss, neurite retraction, and the appearance of other
abnormalities such as axonal transport defects. This pro-
gression argues that cell death programs may play at best
only a secondary role in the neurodegenerative process.
However, emerging evidence from numerous laboratories
has suggested an alternative possibility: that although cell
death itself occurs late in the degenerative process, the
pathways involved in cell death signaling do indeed play
critical roles in neurodegeneration, both in sub-apoptotic
events such as synapse loss and in the ultimate neuronal
loss itself [1-4].
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Although initial comparisons of the intrinsic suicide pro-
gram in genetically tractable organisms such as the nema-
tode C. elegans failed to disclose obvious relationships to
genes associated with human neurodegenerative diseases
– e.g., presenilin-1 and the β-amyloid precursor protein
(APP) do not bear an obvious relationship to any of the
major C. elegans cell death genes (ced-3, ced-4, or ced-9) –
more recent studies have begun to disclose a fundamental
relationship between developmental and degenerative
processes [1,4-8]. For example, Nikolaev and Tessier-
Lavigne found that trophic factor withdrawal from devel-
oping neurons results in neurite retraction that is medi-
ated by a cleavage product of sAPPβ [1]. A detailed
understanding of the interrelationship between funda-
mental cell death programs and neurodegenerative proc-
esses is still evolving, and it promises to offer novel
approaches to the treatment of these diseases.
Caspases: activation and role in programmed 
cell death
Apoptosis (Fig. 1) has been studied extensively, with over
100,000 papers published on the subject http://
www.pubmed.gov. Morphologically, cells typically round
up, form blebs, undergo zeiosis (an appearance of boil-
ing), chromatin condensation, nuclear fragmentation,
and the budding off of apoptotic bodies. Phosphatidylser-
ine, normally placed asymmetrically such that it faces
internally rather than externally on the plasma membrane
(due to a flipase that flips the phosphatidlyserine so that
it faces internally), appears externally during apoptosis
[9]. These morphological and histochemical changes are
largely the result of the activation of a set of cell-suicide
cysteine proteases referred to as caspases (Table 1)
[10,11]. The characteristics of these proteases are
described more fully below.
Programmed cell death pathways may be divided generally into intrinsic and extrinsic pathways Figure 1
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The biochemical activation of apoptosis occurs through
two general pathways (Fig. 1): the intrinsic pathway,
which is mediated by the mitochondrial release of cyto-
chrome c and resultant activation of caspase-9; and the
extrinsic pathway, originating from the activation of cell
surface death receptors such as Fas, resulting in the activa-
tion of caspase-8 or -10 [12]. A third general pathway,
which is essentially a second intrinsic pathway, originates
from the endoplasmic reticulum and also results in the
activation of caspase-9 [13-17]. In addition, other
organelles, such as the nucleus and Golgi apparatus, also
display damage sensors that link to apoptotic pathways
[18]. Thus, damage to any of several different cellular
organelles may lead to the activation of the apoptotic
pathway.
Activation of the intrinsic pathway of apoptosis (e.g., by
DNA damage) leads to cytochrome c release from the
mitochondria, and the released cytochrome c interacts
with a cytosolic protein, Apaf-1, via the WD-40 repeats of
Apaf-1, leading to the exposure of a (d)ATP-binding site
on Apaf-1, which, when occupied, induces a conforma-
tional change resulting in heptamerization. The resultant
exposure of the Apaf-1 CARD (caspase activation and
recruitment domain) recruits caspase-9 into this apopto-
somal complex, and the resulting induced proximity of
caspase-9 molecules leads to their activation [19]. Activa-
tion of the apical caspase-9 leads to a cascade of caspase
activation, including the downstream, effector caspases,
such as caspase-3 and caspase-7. However, the active cas-
pases-3, 7, and 9 can be held in check by the IAP (inhibi-
tor of apoptosis) proteins, such as XIAP [20], which may
function as both direct inhibitors of caspase activity (in
the case of caspase-9, by inhibiting dimerization) and as
E3 ligases that mediate caspase degradation by the protea-
some [21]. This IAP-mediated block may itself be released
by additional mitochondrially-derived proteins, Smac/
DIABLO [22,23] and Omi/HtrA2 [24,25]. Smac ("second
mitochondrial activator of apoptosis"), for example,
binds to IAP proteins, preventing their inhibition of cas-
pases, thus allowing caspase activation despite the pres-
ence of the otherwise inhibitory IAP proteins.
As opposed to the intrinsic pathway, which utilizes cas-
pase-9 as its apical caspase, the extrinsic pathway utilizes
caspase-8 or caspase-10. In the best characterized exam-
ple, Fas is bound by trimeric Fas ligand, resulting in the
interaction of an intracytoplasmic domain of Fas, dubbed
the death domain, with a similar death domain in an
adaptor molecule, FADD (Fas-associated death domain
protein). FADD displays, in addition to its death domain,
another domain called a DED (death effector domain),
and this domain interacts with a similar DED domain in
caspase-8 [26]. The induced proximity of the apical cas-
pase again leads to activation, as is the case for caspase-9.
Also as for caspase-9, the initial caspase activation allows
this upstream caspase to attack downstream, effector pro-
caspases (somewhat analogous to what occurs in the
thrombotic cascade, except that cysteine aspartyl-specific
proteases (caspases) are utilized instead of serine pro-
teases), cleaving and activating the effector caspases such
as caspase-3 and caspase-7. In addition, FLIP(L) (FLICE-
like inhibitory protein, long form), previously considered
an inhibitor of extrinsic pathway activation, may act as a
caspase-8 activator by functioning as a preferable dimeric
partner of caspase-8 (over caspase-8 itself), resulting in
activation by heterodimerization of what would other-
wise be activated less readily by homodimerization [27].
Both the intrinsic and extrinsic pathways of apoptosis
thus converge on the activation of effector caspases by ini-
tiator caspases. Caspases are cysteine aspartyl-specific pro-
teases that cleave with remarkable specificity at a small
subset of aspartic acid residues. Their substrates, the
number of which is unknown but probably somewhere
between 0.5% and 5% of proteins, contribute to the apop-
totic phenotype in several different ways: for example, fol-
lowing cleavage, their substrates contribute to proteolytic
cascade activation, cellular structural alterations, inactiva-
tion of repair mechanisms (e.g., DNA repair), internucle-
osomal DNA cleavage, phagocytic uptake signaling,
mitochondrial permeabilization, and other effects.
Although the substrates of caspases represent a small
minority of the overall proteomic makeup, in neurode-
generative diseases in general, and in Alzheimer's disease
Table 1: Comparison of the apoptotic caspases.
Caspase Group Cleavage Preference1 Prodomain Comments
Caspase-2 Initiator DAVAD CARD
Caspase-3 Executioner DEVD Short
Caspase-6 Executioner VEVD Short Implicated in neurite retraction [4]
Caspase-7 Executioner DEVD Short
Caspase-8 Initiator IETD DED Extrinsic pathway
Caspase-9 Initiator LEHD CARD Intrinsic pathway
Caspase-10 Initiator (similar to caspase-8) DED Extrinsic pathway
1. Note that preferences do not exclude cleavage at other sites with Asp in the P1 position, and that the P1' position is also important (see text).Molecular Neurodegeneration 2009, 4:27 http://www.molecularneurodegeneration.com/content/4/1/27
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in particular, these substrates are over-represented: APP
(and its related family members APLP1 and APLP2), the
presenilins, and tau are all caspase substrates [28-32].
Caspases are synthesized as zymogens, but differ mark-
edly in their activation: the initiator caspases (caspase-8, -
9, and -10) exist as intracytoplasmic monomers until
dimerization is effected by adaptor molecules, such as
FADD. Contrary to earlier assumptions, cleavage of apical
caspases is neither required nor sufficient for activation
[33]. The zymogenicity – i.e., the ratio of activity of the
active form to that of the zymogen – of these caspases is
relatively low, in the range of 10–100 [33], and thus the
(monomeric) zymogens themselves are actually some-
what active. These caspases display relatively large prodo-
mains that are utilized in the protein-protein interactions
that mediate activation – CARD (caspase activation and
recruitment domain) in caspase-9, and DED (death effec-
tor domain) in caspase-8 and -10. The substrates of the
initiator caspases typically display I/L/V-E-X-D in the P4-
P1 positions (with cleavage just carboxyterminal to the P1
residue), with preference for small or aromatic residues in
the P1' position [33].
The apical caspases activate effector caspases such as cas-
pase-3 and -7. In contrast to the apical caspases, the effec-
tor caspases exist as dimers within the cell, display high
zymogenicity (greater than 10,000 for caspase-3) and
short prodomains, and are activated by cleavage rather
than induced proximity. Cleavage produces a tetramer
with two large subunits of 17–20 kilodaltons and two
small subunits of 10–12 kilodaltons. Because of a differ-
ence in the S4 pocket (which interacts with the P4 residue
on the substrate) structure of these caspases (in compari-
son to the apical caspases), with similarity in the S1 and
S3 pockets, their substrate preference is D-E-X-D, with a
two orders of magnitude preference for Asp over Glu in
the P4 position [33].
Caspases that do not fit squarely within these two groups
include caspase-2, which displays a long prodomain like
an apical caspase but has a substrate preference more sim-
ilar to effector caspases (with the exception that, unlike
other caspases, it also has a P5 preference (for small
hydrophobic residues)); caspase-6, which has a short pro-
domain like effector caspases yet a substrate preference
similar to apical caspases; and the inflammatory caspases
(-1, -4, -5) involved in the processing of interleukin-1β
and interleukin-18. These latter are thought not to play a
role in pcd; however, inhibition in some paradigms such
as cerebral ischemia has indeed been associated with a
reduction in infarct size [34].
Caspase-12 is anomalous: in the murine system, it
appears to play a role in apoptosis induced by endoplas-
mic reticulum (ER) stress [15,17,35]. However, murine
caspase-12 lacks Arg341, which in other caspases is critical
for the Asp specificity in the P1 position [33], and instead
features a Lys in this position. Nonetheless, proteolytic
activity has been reported for caspase-12 [17], catalytically
inactive caspase-12 inhibits ER stress-induced apoptosis
[15], caspase-uncleavable caspase-12 also inhibits ER
stress-induced apoptosis, and mice null for caspase-12 are
less susceptible to amyloid-β toxicity than wild type mice
[35]. In the great majority of humans, however, a non-
sense mutation is present in the caspase-12 gene, prevent-
ing expression of an active caspase [36]. Those without
such a mutation are at increased risk for sepsis, due to the
attenuation of the immune response to endotoxins such
as lipopolysaccharide [37].
Caspase activation in neurodegeneration: 
association or requirement?
Evidence for caspase activation in neurodegeneration has
been derived both from the use of antibodies directed
against newly-exposed proteolysis-dependent epitopes
(neo-epitopes) generated by caspase cleavage [4,6,38] and
from the inhibition of neurodegeneration by caspase
inhibitors [39,40]. One of the critical goals for dissecting
the relationship between pcd and neurodegeneration is to
determine the specificity of the trigger: specifically, is neu-
rodegeneration the result of an imbalance in physiologi-
cal signaling events (analogous to what occurs in
neoplasia) or, as more commonly suggested, the result of
a relatively nonspecific toxic effect of a peptide or protein
aggregate? If the latter, then secondary neurodegeneration
may occur due to loss of trophic support, excitotoxicity, or
any number of other secondary effects. If the former, then
specific, physiologically-relevant transduction events that
underlie neurite retraction and synapse loss may poten-
tially be triggered directly by neurodegeneration-associ-
ated transcriptional and post-transcriptional events. In
other words, is neurodegeneration analogous to cancer in
being an imbalance in physiological signals (not from
oncogenes and tumor suppressor genes, but those that
mediate synaptic maintenance and synaptic re-organiza-
tion)? Evidence on both sides exists: for example, numer-
ous toxic properties have been attributed to the Aβ
peptide, such as reactive oxygen species generation and
metal binding, among others [41]. However, signal trans-
duction effects have also been attributed to Aβ peptide,
such as binding and multimerization of amyloid precur-
sor protein, with resultant complex formation and direct
caspase activation [42].
Since the neurodegenerative process may be induced by
widely varying insults – from misfolded proteins to reac-
tive oxygen species to caspase recruitment complexes, as
well as other mechanisms – and yet produce a relatively
small number of syndromes, the existence of a death net-Molecular Neurodegeneration 2009, 4:27 http://www.molecularneurodegeneration.com/content/4/1/27
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work is suggested. The putative network may be entered
from many different sites, but once triggered, would fol-
low similar interdependent biochemical pathways, with
little dependence on the point of entry. This notion is
compatible with the findings that therapeutics aimed at
different pathways (caspase activation, mitochondrial
release of cytochrome c, metal binding, reactive oxygen
species scavenging, etc.) all exert partially salutary effects.
However, it also suggests that a complete halt of the neu-
rodegenerative process may require therapeutics that
address all of the network's interacting pathways.
Trophic factors and cellular dependence in 
Alzheimer's disease
Neurons, as well as other cells, depend for their survival
on stimulation that is mediated by various receptors and
sensors, and pcd may be induced in response to the with-
drawal of trophic factors, hormonal support, electrical
activity, extracellular matrix support, or other trophic
stimuli [43]. For years it was generally assumed that cells
dying as a result of the withdrawal of required stimuli did
so because of the loss of a positive survival signal, for
example mediated by receptor tyrosine kinases [44].
While such positive survival signals are clearly extremely
important, data obtained over the past 15 years argue for
a complementary effect that is pro-apoptotic, activated by
trophic stimulus withdrawal, and mediated by specific
receptors dubbed "dependence receptors" [45,46]. Over a
dozen such receptors have now been identified, and
examples include DCC (deleted in colorectal cancer),
Unc5H2 (uncoordinated gene 5 homologue 2), neo-
genin, RET, Ptc, and APP [46-50]; [51-55]. These receptors
interact in their intracytoplasmic domains with caspases,
including apical caspases such as caspase-9, and may
therefore serve as sites of induced proximity and activa-
tion of these caspases. Caspase activation leads in turn to
receptor cleavage, producing pro-apoptotic fragments
[48,56]; however, mutation of the caspase cleavage sites of
dependence receptors suppresses pcd mediated by the
receptors [45,48]. A striking example of this effect was
obtained in studies of neural tube development: with-
drawal of Sonic hedgehog from the developing chick spi-
nal cord led to apoptosis mediated by its receptor,
Patched, preventing spinal cord development; however,
transfection of a caspase-uncleavable mutant of Patched
blocked apoptosis and restored significant development,
even in the absence of Sonic hedgehog [57].
Thus cellular dependence on specific signals for survival is
mediated, at least in part, by specific dependence recep-
tors that induce apoptosis in the absence of the required
stimulus – when unoccupied by a trophic ligand, or when
bound by a competing, anti-trophic ligand – but block
apoptosis following binding to their respective ligands
[43,46,49]. Expression of these dependence receptors
therefore creates cellular states of dependence on the asso-
ciated trophic ligands. These states of dependence are not
absolute, since they can be blocked downstream in some
cases by the expression of anti-apoptotic genes such as bcl-
2 or p35 [43,47,58]; however, they result in a shift of the
apostat [12,59] toward an increased likelihood of trigger-
ing apoptosis. In the aggregate, these receptors may serve
as a molecular integration system for trophic signals, anal-
ogous to the electrical integration system comprised of the
dendritic arbors within the nervous system.
Cellular dependence on trophic signals was originally
described in the developing nervous system, but neurode-
generation may utilize the same pathways: the β-amyloid
precursor protein (APP) exhibits several features charac-
teristic of dependence receptors, including an intracyto-
plasmic caspase cleavage site (Asp664) [31,32], co-
immunoprecipitation with an apical caspase (caspase-8),
caspase activation, derivative pro-apoptic peptides (see
below), and suppression of apoptosis induction by muta-
tion of the caspase cleavage site. [31,42].
These findings raise several questions: first, does the cas-
pase cleavage of APP occur in human brain, and, if so, is
this increased in patients with Alzheimer's disease? Sec-
ond, if this cleavage is prevented, is the Alzheimer's phe-
notype affected? Third, is there a physiological role for this
cleavage event? These questions are addressed below.
Alzheimer's disease: an imbalance in cellular 
dependence?
Extensive genetic and biochemical data have implicated
the Aβ peptide as a central mediator of Alzheimer's dis-
ease, but the mechanism(s) of action remains controver-
sial: some have emphasized the ability of Aβ to generate a
sulfuranyl radical involving methionine 35, others have
focused on the metal-binding property of Aβ, others have
pointed to its aggregating property, and still others have
implicated its detergent-like effects on some membranes,
just to list a few of the mechanisms proposed [41]. These
proposed mechanisms share a focus on the chemical and
physical properties of the Aβ peptide. However, cellular
signaling is emerging as a complementary mechanism by
which Aβ exerts its critical effects, and multiple candidates
have surfaced as key downstream mediators, including
APP itself, the insulin receptor, and tau, among others
[42,60,61]. These cellular signals may also mediate neuro-
nal dependence on trophic support, as described below.
Neo-epitope antibodies directed against residues 657–
664 of human APP disclosed the presence of caspase-
cleaved APP fragments in human brain (Fig. 2), especially
in the hippocampal region [7], with an approximately
four-fold increase in Alzheimer's patients over age-
matched controls. However, in brains without Alzhe-Molecular Neurodegeneration 2009, 4:27 http://www.molecularneurodegeneration.com/content/4/1/27
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imer's pathology, there was an inverse relationship
between age and immunohistochemical detection of APP-
neo, with a different distribution than in AD brains:
whereas, in the Alzheimer brains, the staining was prima-
rily in somata, in the non-Alzheimer brains, the staining
was observed predominantly in the processes. These find-
ings suggest that the caspase cleavage of APP occurs phys-
iologically and is reduced with age, but that this process
remains more active in association with Alzheimer's dis-
ease.
The effect of preventing the caspase cleavage of APP on the
Alzheimer's phenotype was evaluated in AD model trans-
genic mice that express APP with Swedish and Indiana
mutations that are associated with familial Alzheimer's
disease. Although the caspase mutation (D664A) had no
effect on plaque formation, or on the production of Aβ
peptides 1–40 or 1–42, the D664A mutation prevented
the synapse loss, early p21-activated kinase (PAK) phos-
phorylation, dentate gyral atrophy, electrophysiological
abnormalities (including reductions in excitatory post-
synaptic potentials (EPSPs) and long-term potentiation
(LTP)), neophobia, and memory deficits that characterize
Alzheimer model mice [2,4,62]. These findings indicate
that key features of the Alzheimer's phenotype, at least in
a standard transgenic mouse model, depend on the pres-
ence of the caspase cleavage site within APP. Yet, as noted
above, extensive previous work has shown that the pheno-
type is critically dependent on Aβ, suggesting that the APP
caspase site may lie downstream from the Aβ accumula-
tion that is unaffected by the D664A mutation [42,61].
This possibility has received support from studies show-
ing that Aβ interacts directly with APP in the Aβ region
itself, leading to multimerization, caspase cleavage, and
cell death signaling [42,61].
If APP does indeed function as a dependence receptor,
Alzheimer's disease may be considered a "state of altered
dependence" (Appendix 1). What then is/are the trophic
ligand(s) for APP? Several candidate APP interactors have
been described, such as collagen (types I and IV), heparan
sulfate proteoglycan, laminin, glypican, and F-spondin
[63-65]. In the case of F-spondin's interaction with APP,
β-secretase activity is reduced. Lourenco et al. have
recently shown that netrin-1, a multifunctional axon guid-
ance and trophic factor, also binds APP [8]. Furthermore,
netrin-1 also interacts with Aβ itself, and thus Aβ may
interfere with netrin-1 binding to APP. The binding of
netrin-1 to APP results in enhanced interaction of APP
with Fe65 and Dab, up-regulation of KAI1, and a marked
reduction of net Aβ production [8].
These findings suggest a model in which the Aβ peptide
functions as an anti-trophin, blocking netrin's guidance
and trophic effects, binding and oligomerizing APP,
recruiting and activating caspases, engendering the
processing of APP at Asp664, and inducing neurite retrac-
tion, and, ultimately, neuronal cell death [4,42,61,66].
Whether the D664A mutation of APP exerts effects
beyond the prevention of caspase cleavage (e.g., an altera-
tion of the intracytoplasmic structure of APP) is not yet
known. However, irrespective of the mechanism, the
results suggest that APP signal transduction may be
important in mediating Alzheimer's disease [67], at least
in the transgenic mouse model, possibly downstream
from Aβ oligomerization and binding of APP.
The results obtained in the transgenic mouse model of AD
also suggest an alternative to the classic models of AD. As
noted above, chemical and physical properties of Aβ have
been cited as the proximate cause of AD pathophysiology.
However, these theories do not explain why Aβ is pro-
duced ubiquitously and constitutively, nor do they offer a
physiological function for the Aβ peptide, or account for
the improvement in AD model mice that occurs with a
reduction in tau protein [60].
An alternative model, presented in Figs. 3 and 4, argues
that APP is indeed a dependence receptor, and that it func-
tions normally as a molecular switch in synaptic element
interdependence: in this model, both the pre-synaptic ele-
ment and the post-synaptic element are dependent on
trophic support, including soluble factors such as netrin,
substrate molecules such as laminin, neurotransmitters,
Caspase cleavage of APP, indicated by immunohistochemical  detection of the APP664 neo-epitope, in the brain of a  patient with Alzheimer's disease Figure 2
Caspase cleavage of APP, indicated by immunohisto-
chemical detection of the APP664 neo-epitope, in 
the brain of a patient with Alzheimer's disease. Note 
perinuclear cytoplasmic staining in the granular cell layer of 
the hippocampus (black vertical arrows) as well as intense, 
apparently extracellular plaque-like deposits (yellow horizon-
tal arrows).Molecular Neurodegeneration 2009, 4:27 http://www.molecularneurodegeneration.com/content/4/1/27
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and neuronal activity, as well as other factors. In the pres-
ence of adequate trophic support, APP is cleaved at the
alpha and gamma sites, generating three peptides –
sAPPα, p3, and AICD – that support cell survival and syn-
aptic maintenance. However, a reduction in trophic sup-
port alters the processing of APP, reducing the α/β ratio of
cleavage, and leading to the production of four peptides –
sAPPβ, Aβ, Jcasp, and C31 – that mediate a reduction in
synaptic transmission, synaptic loss, neurite retraction
and, ultimately, programmed cell death [1,4,8,31,62]. In
this model, Alzheimer's disease is suggested to be an
imbalance in physiological signaling pathways that medi-
ate synaptic maintenance vs. synaptic re-organization,
mediated at least in part by APP, functioning in synaptic
element interdependence, as part of a plasticity module
that includes other receptors such as the common neuro-
trophin receptor, p75NTR and the axon guidance receptor
DCC, among others [68] (see Appendix 2 regarding pro-
posed follow-up studies). It is important to note that mul-
tiple groups have described a pro-apoptotic effect of
AICD, in contrast to the model proposed here (e.g.,
[69,70]); however, since AICD can be cleaved at Asp664
to give rise to two pro-apoptotic peptides – Jcasp and C31
– it is critical to evaluate AICD with a mutation that pre-
vents this caspase cleavage, and previous studies have not
included these data. Thus the pro-apoptotic effect attrib-
uted to AICD may be due to its ability to give rise to Jcasp
and C31.
Conclusion
We present here a model for Alzheimer's disease that is
based not on chemically and physically-mediated toxic
effects of Aβ, but on imbalanced signal transduction. The
model suggests that the imbalance lies in the ratio of the
signals that mediate synaptic maintenance, neurite exten-
sion, and cell survival vs. those that mediate synaptic reor-
ganization, neurite retraction, and programmed cell death
– essentially, memory retention vs. forgetting and mem-
ory reorganization. This model suggests that Aβ has a
physiological function as a neuromodulatory peptide,
and at least in some cases that it functions as an anti-
trophin – competing, for example, with netrin-1 for bind-
ing to APP. Whether it has analogous functions related to
its described interactions with other receptors, such as
PrP, p75NTR, and RAGE, remains to be determined. This
model also proposes that synaptic element interdepend-
ence is a critical factor in synaptic maintenance vs. reor-
ganization, with associated effects on memory retention
vs. loss. Both pre-synaptic and post-synaptic elements
Alternative cleavage of APP to produce four peptides that  mediate synaptic loss, neurite retraction, and ultimately pro- grammed cell death ("the four horsemen"); or three peptides  that mediate synaptic maintenance and inhibit programmed  cell death ("the wholly trinity") Figure 3
Alternative cleavage of APP to produce four pep-
tides that mediate synaptic loss, neurite retraction, 
and ultimately programmed cell death ("the four 
horsemen"); or three peptides that mediate synaptic 
maintenance and inhibit programmed cell death 
("the wholly trinity"). Among the factors that mediate the 
decision between these two pathways are included trophic 
effects such as netrin-1 and anti-trophic effects such as Aβ 
peptide.
Synaptic element interdependence model of synaptic mainte- nance, reorganization, and Alzheimer's disease Figure 4
Synaptic element interdependence model of synaptic 
maintenance, reorganization, and Alzheimer's dis-
ease. The pre-synaptic and post-synaptic elements are inter-
dependent, and provide both trophic influences (e.g., 
neurotrophins, netrin-1, laminin, collagen, and synaptic activ-
ity itself) and anti-trophic influences (e.g., amyloid-β peptide). 
Trophic support leads to the processing of APP into three 
peptides that support synaptic maintenance, whereas the 
withdrawal of trophic support leads to alternative process-
ing, to four peptides that mediate synaptic inhibition, synaptic 
loss, neurite retraction, and ultimately, programmed cell 
death. In this model, the Aβ peptide functions as an anti-
trophin, and, since it leads to APP processing that produces 
additional Aβ peptide, it is "prionic", i.e., Aβ begets additional 
Aβ.Molecular Neurodegeneration 2009, 4:27 http://www.molecularneurodegeneration.com/content/4/1/27
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exert trophic and anti-trophic influences on each other,
and the balance determines whether synaptic mainte-
nance or reorganization will occur. The molecular details
of the model are summarized in Fig. 4.
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ligases: E3-ubiquitin protein ligases; ER: endoplasmic
reticulum; EPSP: excitatory post-synaptic potential;
FADD: Fas-associated death domain protein; FLIP(L):
FLICE-like inhibitory protein, long form; Glu: glutamate;
I/L/V-E-X-D: isoleucine/leucine/valine-glutamate-any
amino acid-aspartate; IAP: inhibitor of apoptosis protein;
Jcasp: juxtamembrane fragment of APP produced by cas-
pase cleavage and gamma-secretase cleavage; KAI1: Kan-
gai 1 (suppression of tumorigenicity 6, prostate; CD82
antigen (R2 leukocyte antigen, antigen detected by mono-
clonal and antibody IA4)); LTP: long-term potentiation;
Lys: lysine; Neo-epitopes: newly-exposed proteolysis-
dependent epitopes; Omi/HtrA2: mitochondrial serine
protease that antagonizes IAP proteins; PAK: p21-acti-
vated kinase; p3: peptide of approximately three kilodal-
tons, derived from APP by cleavage at the alpha-secretase
site and the gamma-secretase site; p35: protein of approx-
imately 35 kilodaltons that inhibits caspases; derived
from baculovirus; P4 position: fourth amino acid aminot-
erminal to the cleavage site of a given protease; p75NTR:
common neurotrophin receptor; pcd: programmed cell
death; Ptc: patched protein; RET: rearranged during trans-
fection; S1 and S3 pockets: pockets of the protease that
interact with the P1 and P3 residues of the substrate,
respectively; sAPPα: soluble fragment of APP derived from
the cleavage by alpha-secretase; sAPPβ: soluble fragment
of APP derived from the cleavage by beta-secretase; Smac/
DIABLO: second mitochondrial activator of apoptosis
protein/DIABLO protein; Unc5H2: uncoordinated gene 5
homologue 2; WD-40 domain: protein binding motif that
contains ~7 regions ~40 amino acids long containing a
conserved tryptophan and aspartic acid; XIAP: inhibitor of
apoptosis protein X.
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Appendix 1: Key Observations
￿ Caspase cleavage may be critical in both apoptotic and
sub-apoptotic events (e.g., synapse loss) in neurodegener-
ative disease.
￿ APP exhibits the characteristics of a dependence recep-
tor.
￿ APP may be cleaved in two alternative patterns: to pro-
duce four peptides that mediate synaptic loss, neurite
retraction, and ultimately programmed cell death ("the
four horsemen"); or three peptides that mediate synaptic
maintenance and inhibit programmed cell death ("the
wholly trinity"). Among the factors that mediate the deci-
sion between these two pathways are included trophic
effects such as netrin-1 and anti-trophic effects such as Ab
peptide.
￿ A model of Alzheimer's disease is presented that is based
on synaptic element interdependence, imbalanced signal
transduction, and caspase activation. In this model, the
amyloid-beta peptide functions as an anti-trophin and
exhibits "prionic" positive feedback.
Appendix 2: Critical Next Steps
￿ Evaluate transgenic mice producing alternative peptides:
the "four horsemen" or the "wholly trinity".
￿ Establish the structural basis of the interactions between
APP and netrin-1; and between APP and the amyloid-beta
peptide.
￿ Characterize the signaling network that mediates the
neurite retractive, pro-Alzheimer's phenotype vs. the syn-
aptic maintenance, anti-Alzheimer's phenotype.
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